$ARTV
Artiva Biotherapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$5.90
▼-0.17%-$0.010
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateArtiva Biotherapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is ARTV down today? It is at $5.90 (-0.17%), and our scanner flagged it 74 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ARTV spikes, and full due diligence on ARTV — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ARTV 74 times in the last 30 days. Create a free account to track $ARTV, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on ARTV from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ARTV today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Latest filing4Insider trade (Form 4)Oct 8, 2026 · 7 days agoAcross every filing on file, supply equal to 525.2% of the tradeable float is in play - 525.2% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
26,041,664 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · Priced at $11.52/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Aslan Fred Officer | Sold (automatic/other) | -23K 0.05% of company | sold 1.5% | 1.52M | $169K at $7.20 | Oct 6, 26 |
Aslan Fred Officer | Sold (automatic/other) | -62K 0.1% of company | sold 3.8% | 1.54M | $422K at $6.84 | Oct 5, 26 |
Banerjee Subhashis Officer | Sold (automatic/other) | -1K | sold 0.6% | 170K | $8K at $6.84 | Oct 5, 26 |
Bush Jennifer Officer | Sold (automatic/other) | -8K 0.02% of company | sold 2.2% | 366K | $57K at $6.84 | Oct 5, 26 |
Horan Christopher Officer | Sold (automatic/other) | -10K 0.02% of company | sold 3.2% | 313K | $71K at $6.84 | Oct 5, 26 |
Aslan Fred Officer | Acquired (grant/award) | +110K 0.2% of company | added 7.4% | 1.60M | n/a | Sep 15, 26 |
Aslan Fred Officer | Acquired (grant/award) | +45K 0.09% of company | added 3.1% | 1.49M | n/a | Sep 10, 26 |
Banerjee Subhashis Officer | Acquired (grant/award) | +30K 0.06% of company | added 21% | 171K | n/a | Sep 9, 26 |
Bush Jennifer Officer | Acquired (grant/award) | +45K 0.09% of company | added 14% | 375K | n/a | Sep 9, 26 |
Horan Christopher Officer | Acquired (grant/award) | +40K 0.08% of company | added 14% | 323K | n/a | Sep 9, 26 |
Miralles Gines Diego Officer | Acquired (grant/award) | +45K 0.09% of company | added 58% | 123K | n/a | Sep 9, 26 |
Aslan Fred Officer | Sold (automatic/other) | -23K 0.05% of company | sold 1.6% | 1.45M | $256K at $10.92 | Sep 8, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on ARTV from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for ARTV today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
ARTV last traded at $5.90, down 0.17% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is next expected to report earnings on Wednesday, November 11, 2026, about 27 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ARTV Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ARTV 74 times in the last 30 days.
ARTV (Artiva Biotherapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $289M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ARTV for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ARTV discussion
Sign in to ask a question or join the discussion.